108 related articles for article (PubMed ID: 23450519)
1. Skin necrosis induced by generic enoxaparin.
Gucalp A; Parameswaran R; Lacouture M; Abou-Alfa G; Soff G
Am J Hematol; 2013 Apr; 88(4):339. PubMed ID: 23450519
[No Abstract] [Full Text] [Related]
2. Structure and haemostatic effects of generic versions of enoxaparin available for clinical use in Brazil: similarity to the original drug.
Glauser BF; Vairo BC; Oliveira SN; Cinelli LP; Pereira MS; Mourão PA
Thromb Haemost; 2012 Feb; 107(2):302-14. PubMed ID: 22234635
[TBL] [Abstract][Full Text] [Related]
3. [Enoxaparin induced skin necrosis].
Scharf Y; Hershkoviz R
Harefuah; 2003 Nov; 142(11):742-3, 807. PubMed ID: 14631903
[TBL] [Abstract][Full Text] [Related]
4. Biomarkers and coagulation tests for assessing the biosimilarity of a generic low-molecular-weight heparin: results of a study in healthy subjects with enoxaparin.
Kuczka K; Harder S; Picard-Willems B; Warnke A; Donath F; Bianchini P; Parma B; Blume H
J Clin Pharmacol; 2008 Oct; 48(10):1189-96. PubMed ID: 18716314
[TBL] [Abstract][Full Text] [Related]
5. Recurrent life-threatening deep tissue hematomas after switching to generic enoxaparin: a report and perspective on the approval process for biological compounds.
Kaffenberger BH; Bekaii-Saab T
Clin Appl Thromb Hemost; 2012; 18(1):104-6. PubMed ID: 21873360
[TBL] [Abstract][Full Text] [Related]
6. Bioequivalence of generic and branded subcutaneous enoxaparin: a single-dose, randomized-sequence, open-label, two-period crossover study in healthy Chinese male subjects.
Feng L; Shen-Tu J; Liu J; Chen J; Wu L; Huang M
Clin Ther; 2009 Jul; 31(7):1559-67. PubMed ID: 19695405
[TBL] [Abstract][Full Text] [Related]
7. An open label, non-randomized, prospective clinical trial evaluating the immunogenicity of branded enoxaparin versus biosimilars in healthy volunteers.
Gomes M; Ramacciotti E; Hoppensteadt D; Walenga JM; Lewis B; Thethi I; Fareed J
Clin Appl Thromb Hemost; 2011 Feb; 17(1):66-9. PubMed ID: 21220365
[TBL] [Abstract][Full Text] [Related]
8. Enoxaparin-induced skin necrosis.
Fried M; Kahanovich S; Dagan R
Ann Intern Med; 1996 Sep; 125(6):521-2. PubMed ID: 8779482
[No Abstract] [Full Text] [Related]
9. [Concerns on generic enoxaparin use in acute coronary syndrome].
Gomes M; Ramacciotti E; Litinas E; Fareed J
Arq Bras Cardiol; 2010 Oct; 95(4):551-2. PubMed ID: 21180789
[No Abstract] [Full Text] [Related]
10. JAAD grand rounds quiz. Dusky bullae on the abdomen.
Schleich C; Hansen TJ; Kirby JS
J Am Acad Dermatol; 2014 Nov; 71(5):1033-5. PubMed ID: 25437975
[No Abstract] [Full Text] [Related]
11. [Enoxaparin-induced cutaneous necrosis localized on insulin lipodystrophies].
Lefebvre I; Delaporte E; Dejobert Y; Catteau B; Piette F; Bergoend H
Ann Dermatol Venereol; 1997; 124(5):397-400. PubMed ID: 9739898
[TBL] [Abstract][Full Text] [Related]
12. Enoxaparin-induced Skin Necrosis.
Neloska L; Damevska K; Pavleska L
Acta Dermatovenerol Croat; 2015; 23(3):223-4. PubMed ID: 26476910
[No Abstract] [Full Text] [Related]
13. Bullous hemorrhagic dermatosis induced by enoxaparin.
Gouveia AI; Lopes L; Soares-Almeida L; Filipe P
Cutan Ocul Toxicol; 2016; 35(2):160-2. PubMed ID: 25942690
[TBL] [Abstract][Full Text] [Related]
14. Generic warfarin: implications for patient care.
Wittkowsky AK
Pharmacotherapy; 1997; 17(4):640-3. PubMed ID: 9250543
[No Abstract] [Full Text] [Related]
15. Generic warfarin: implications for patient care--another view.
Meyer M; Chan K; Bolton S
Pharmacotherapy; 1998; 18(4):884-6; discussion 887-9. PubMed ID: 9692670
[No Abstract] [Full Text] [Related]
16. Hemorrhagic and thrombotic events associated with generic substitution of warfarin in patients with atrial fibrillation: a retrospective analysis.
Ghate SR; Biskupiak JE; Ye X; Hagan M; Kwong WJ; Fox ES; Brixner DI
Ann Pharmacother; 2011 Jun; 45(6):701-12. PubMed ID: 21666081
[TBL] [Abstract][Full Text] [Related]
17. A fatal case of enoxaparin induced skin necrosis and thrombophilia.
Nadir Y; Mazor Y; Reuven B; Sarig G; Brenner B; Krivoy N
Eur J Haematol; 2006 Aug; 77(2):166-8. PubMed ID: 16856910
[TBL] [Abstract][Full Text] [Related]
18. Active and passive surveillance of enoxaparin generics: a case study relevant to biosimilars.
Grampp G; Bonafede M; Felix T; Li E; Malecki M; Sprafka JM
Expert Opin Drug Saf; 2015 Mar; 14(3):349-60. PubMed ID: 25557261
[TBL] [Abstract][Full Text] [Related]
19. A comparison of the pharmacodynamic behavior of branded and biosimilar enoxaparin in primates.
Jeske W; Litinas E; Khan H; Hoppensteadt D; Fareed J
Clin Appl Thromb Hemost; 2012 Jun; 18(3):294-8. PubMed ID: 22275388
[TBL] [Abstract][Full Text] [Related]
20. Evaluation of Immunostimulatory Potential of Branded and US-Generic Enoxaparins in an In Vitro Human Immune System Model.
Luna E; Agrawal P; Mehta R; Vernhes C; Viskov C; Amiral J; Warren WL; Drake DR
Clin Appl Thromb Hemost; 2015 Apr; 21(3):211-22. PubMed ID: 25525049
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
